This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in North Kansas City, MO, Cerner Corporation (CERN) provides healthcare information technology (HCIT) solutions worldwide. The company offers software and hardware solutions that give healthcare providers secure access to clinical, administrative and financial data in a short time. As of February 2018, its products were in use at more than 27,000 facilities around the world. The company had more than 28,000 employees globally, with over 13,000 in Kansas City, Missouri. More than 28,000 Cerner associates are currently employed in 26 countries worldwide
Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.
Cerner (CERN) Stock Moves -0.37%: What You Should Know
by Zacks Equity Research
Cerner (CERN) closed the most recent trading day at $91.37, moving -0.37% from the previous trading session.
Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy
by Zacks Equity Research
Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
BD (BDX) Hits a New 52-Week High: What's Behind the Rally?
by Zacks Equity Research
A slew of strategic acquisitions are driving the top line for BD (BDX).
OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment
by Zacks Equity Research
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP
by Zacks Equity Research
Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent (CTLT) to Advance Oral Drug Development With New Launch
by Zacks Equity Research
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.
PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues
by Zacks Equity Research
PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.
AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.
Here's Why You Should Retain Cigna (CI) in Your Portfolio
by Zacks Equity Research
Cigna (CI) is well-poised for growth, attributable to solid segmental contributions, the continuous launch of affordable MA plans, a strong partner network and sufficient cash reserves.
Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid
by Zacks Equity Research
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.
Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.
Cerner (CERN) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
Cerner (CERN) closed at $92.55 in the latest trading session, marking a -0.1% move from the prior day.
Walgreens Boots (WBA) Gains From New Pacts, Faces Margin Woes
by Zacks Equity Research
Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly.
Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI Label
by Zacks Equity Research
The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.
Zacks.com featured highlights include: Boston Beer Co. Inc., Williams-Sonoma, Inc., Cerner Corp., PNM Resources and Sonoco Products Co
by Zacks Equity Research
Boston Beer Co. Inc., Williams-Sonoma, Inc., Cerner Corp., PNM Resources and Sonoco Products Co are highlighted in this screen of the week article.
Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain
by Zacks Equity Research
Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) given the strength in the diagnostics business and notable acquisition deals.